World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Prof. Caroline Robert (MD. Ph.D.), a world-renowned expert on Melanoma has joined the company's Board of Advisors.
The announcement follows the company's decision to initiate research aimed at the development of a new Melanoma treatment based on the company's unique expertise and technology.
Dr. Gil Feiler, Director and Advisory Board Chair commented: "It is an exceptionally great honor to have Prof. Robert join our Advisory Board. Caroline is among the world's leading physicians specializing in the field of Melanoma, her groundbreaking research on Melanoma and treatment of Melanoma has been published extensively, including numerous publications in high-authority medical journals such as The New England Journal of Medicine and Nature, to name only a few. We are excited to have Caroline join us, and we look forward to the invaluable input that she will no doubt bring to the company and to our targeted goal of developing a new treatment for Melanoma".
About Prof. Caroline Robert:
Prof. Caroline Robert, M.D., Ph.D., is Head of the Dermatology Unit at Institut Gustave Roussy in Paris, France. She is also co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. Prof. Robert recieved her medical training at Paris V University in France, and later completed a research fellowship in Cancer Immunology and Immunotherapy at Harvard, Brigham & Women's Hospital.
Prof. Robert is the former Chair of the Melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC), and is currently a Board member of the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO), the European Association of Dermato-Venereology (EADV) the French Society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) and the American Association of Clinical Research (AACR).
Her main focuses of interest are clinical and translational research on Melanoma, immunotherapy and targeted therapy, as well as the study of the cutaneous adverse events of anticancer agents. Prof. Robert is a national and international coordinator of numerous clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. She has authored more than 325 articles in peer-reviewed scientific journals, including a number of publications on new treatments for metastatic melanoma. Her more recent work is focused on identification of new biomarkers for immunotherapy and targeted therapies of patients with melanoma.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1-(877)-424-2429
[email protected]
SOURCE Cannabics Pharmaceuticals Inc.
Share this article